Amanda R. Smolock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda R. Smolock has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Sarah B. White
Department of Radiology, Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI
3 shared publications- Kevin Anton
Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
2 shared publications Aaditya Nagaraj
Radiology Partners Houston, Houston, USA
1 shared publicationAllan Roza
Department of Surgery, Medical College of Wisconsin, Milwaukee, USA
1 shared publication- Allison Tan
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication - Andrej Lyshchik
Department of Radiology, Thomas Jefferson University, Philadelphia, PA
1 shared publication
Latest Publications
- 14 February 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (6) , 865-873
Percutaneous Microwave Ablation versus Cryoablation for Small Renal Masses (≤4 cm): 12-Year Experience at a Single Center
- 14 February 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (6) , 865-873
Percutaneous Microwave Ablation versus Cryoablation for Small Renal Masses (≤4 cm): 12-Year Experience at a Single Center
- 13 July 2023
- Published by Springer Nature
- p. 252-254
Neoadjuvant TACE for IVC Leiomyosarcoma with Non-target Embolization
- 13 July 2023
- Published by Springer Nature
- p. 252-254
Neoadjuvant TACE for IVC Leiomyosarcoma with Non-target Embolization
- 31 December 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (4) , 619-622.e1
Vertebral Body Bone Ablation with and without a Saline-Infused System in a Porcine Model
- 31 December 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (4) , 619-622.e1
Vertebral Body Bone Ablation with and without a Saline-Infused System in a Porcine Model
- 19 December 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (2) , 204-208
Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy
Purpose The purpose of this study was to elicit the relationship of antiplatelet therapy (AP) in maintaining arteriovenous graft (AVG) patency after successful percutaneous pharmacomechanical thrombectomy (“declot”). Materials and Methods This was an institutional review board-approved retrospective review of AVG declot procedures between July 2019 and August 2020. AVG characteristics, bleeding complications, anticoagulation and antiplatelet medication regimens, and thrombosis free survival were evaluated. Recurrent time-to-event analysis was performed using a Prentice-Williams-Peterson Gap time model was performed to evaluate AVG thrombosis free survival. Results A total of 109 declots were technically successful and performed in 63 individual patients. The majority of procedures were performed in upper arm grafts (71%, n = 45). Dual antiplatelet (DAPT) was prescribed after 52 declots (48%), single antiplatelet was prescribed after 36 declots (33%), and anticoagulation was prescribed after 31 declots (28%). Median thrombosis free survival was 37 days (range 1–412 days) in the no antiplatelet group, 84 days (range 1–427 days) in the single antiplatelet group, and 93 days (range 3–407 days) in the DAPT group. Anti-platelet medications trended towards protective of AVG thrombosis in multivariate analysis (hazard ratio 0.84, 95% confidence interval 0.60–1.19); however, this did not reach statistical significance (P = 0.33). A total of 4 major and 5 minor bleeding events occurred. Conclusion The results of this study support further evaluation of AP therapy in preventing secondary rethrombosis of dialysis AVG.
- 19 December 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (2) , 204-208
Role of Antiplatelet Therapy in Hemodialysis Arteriovenous Graft Secondary Patency Following Successful Percutaneous Thrombectomy
Purpose The purpose of this study was to elicit the relationship of antiplatelet therapy (AP) in maintaining arteriovenous graft (AVG) patency after successful percutaneous pharmacomechanical thrombectomy (“declot”). Materials and Methods This was an institutional review board-approved retrospective review of AVG declot procedures between July 2019 and August 2020. AVG characteristics, bleeding complications, anticoagulation and antiplatelet medication regimens, and thrombosis free survival were evaluated. Recurrent time-to-event analysis was performed using a Prentice-Williams-Peterson Gap time model was performed to evaluate AVG thrombosis free survival. Results A total of 109 declots were technically successful and performed in 63 individual patients. The majority of procedures were performed in upper arm grafts (71%, n = 45). Dual antiplatelet (DAPT) was prescribed after 52 declots (48%), single antiplatelet was prescribed after 36 declots (33%), and anticoagulation was prescribed after 31 declots (28%). Median thrombosis free survival was 37 days (range 1–412 days) in the no antiplatelet group, 84 days (range 1–427 days) in the single antiplatelet group, and 93 days (range 3–407 days) in the DAPT group. Anti-platelet medications trended towards protective of AVG thrombosis in multivariate analysis (hazard ratio 0.84, 95% confidence interval 0.60–1.19); however, this did not reach statistical significance (P = 0.33). A total of 4 major and 5 minor bleeding events occurred. Conclusion The results of this study support further evaluation of AP therapy in preventing secondary rethrombosis of dialysis AVG.
- 12 September 2022
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 07 (03) , 159-162
Comparison of Outcomes with Triple-Regimen versus Double-Regimen Transarterial Chemoembolization
We sought to evaluate differences in outcomes between double versus triple transarterial chemoembolization (TACE). TACEs over a 1-year period were retrospectively reviewed and divided into two groups: double and triple. Imaging response and complications were made on a per-procedure basis. Student's t-test was used to calculate differences in continuous variables, and chi-square test was used to calculate differences in categorical values.Overall tumor response was similar between the two groups, and there were no significant differences in complications between groups. Outcomes are similar between double and triple conventional TACE, suggesting that adding a third drug may only contribute to cost.
- 12 September 2022
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 07 (03) , 159-162
Comparison of Outcomes with Triple-Regimen versus Double-Regimen Transarterial Chemoembolization
We sought to evaluate differences in outcomes between double versus triple transarterial chemoembolization (TACE). TACEs over a 1-year period were retrospectively reviewed and divided into two groups: double and triple. Imaging response and complications were made on a per-procedure basis. Student's t-test was used to calculate differences in continuous variables, and chi-square test was used to calculate differences in categorical values.Overall tumor response was similar between the two groups, and there were no significant differences in complications between groups. Outcomes are similar between double and triple conventional TACE, suggesting that adding a third drug may only contribute to cost.
- 4 January 2022
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 06 (01) , 037-040
Immune Response to Locoregional Therapy
The immune response to cancer is an ongoing area of interest and is the focus of newer systemic agents. Liver-directed therapy has been the standard treatment for primary and metastatic disease limited to the liver. It is increasingly being recognized that these therapies may influence a broader systemic response and immune activation. The clinical and translational data supporting this phenomenon are reviewed herein. The findings and potential impact of the immune response to liver-directed therapies are summarized in this article. Received: 27 September 2021 Accepted: 24 November 2021 Publication Date: 04 January 2022 (online) © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 4 January 2022
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 06 (01) , 037-040
Immune Response to Locoregional Therapy
The immune response to cancer is an ongoing area of interest and is the focus of newer systemic agents. Liver-directed therapy has been the standard treatment for primary and metastatic disease limited to the liver. It is increasingly being recognized that these therapies may influence a broader systemic response and immune activation. The clinical and translational data supporting this phenomenon are reviewed herein. The findings and potential impact of the immune response to liver-directed therapies are summarized in this article. Received: 27 September 2021 Accepted: 24 November 2021 Publication Date: 04 January 2022 (online) © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 15 December 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (2) , 450-457
US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial
Combined US-triggered microbubble destruction and hepatocellular carcinoma radioembolization showed improved treatment response compared with radioembolization alone and no changes in vital signs o... Background US contrast agents are gas-filled microbubbles (MBs) that can be locally destroyed by using external US. Among other bioeffects, US-triggered MB destruction, also known as UTMD, has been...
- 15 December 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (2) , 450-457
US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial
Combined US-triggered microbubble destruction and hepatocellular carcinoma radioembolization showed improved treatment response compared with radioembolization alone and no changes in vital signs o... Background US contrast agents are gas-filled microbubbles (MBs) that can be locally destroyed by using external US. Among other bioeffects, US-triggered MB destruction, also known as UTMD, has been...